<unk>  is having research published in a peer reviewed journal following clinical<unk> . Most investigators will want to have such a<unk>  but the nature of clinical<unk>  may create special considerations and obstacles. Most agreements for a clinical<unk> between sponsor and investigator grants that the sponsor may control<unk>  of results by requesting<unk>  delays, deleting portions of a manuscript, or placing limits on the types of issues that can be discussed. These controls serve to prevent disclosure of information that would compromise the sponsor's ability to patent inventions; to prevent disclosure of confidential information shared with investigator; and to coordinate the disclosure of results when a clinical<unk> is being conducted at multiple sites. These are legitimate business concerns, but may not restrict the investigator from freely publishing research results in the end of the study and approval process. Due to repeated accusations and findings that some clinical<unk>  conducted or funded by pharmaceutical companies may report only positive results for the preferred medication, the industry has been looked at much more closely by independent groups and government agencies. Issues and responses have included guidelines to limit financial inducements to researchers, journal articles presented as academic research actually being 'ghost-written' by pharmaceutical companies, litigation to deter or suppress<unk>  of negative findings, concerns, or cheaper alternatives. and laws in the United States requiring advanced clinical<unk>  to be registered on a public government website.
Clinical trials publication
Phases of clinical research
Outline of clinical research
Glossary of clinical research
Patient group directions
Operational Research CONsultancy
Clinical research
Clinical research ethics